NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $0.38 -0.03 (-8.20%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.38 0.00 (-1.04%) As of 10/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About KALA BIO Stock (NASDAQ:KALA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KALA BIO alerts:Sign Up Key Stats Today's Range$0.38▼$0.4250-Day Range$0.39▼$0.9552-Week Range$0.38▼$95.50Volume1.05 million shsAverage Volume3.65 million shsMarket Capitalization$7.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview KALA BIO, Inc. is a clinical-stage biotechnology company focused on developing regenerative therapies for rare diseases. The company uses its secretome-based platform, which is designed to harness biologically active proteins, growth factors and other components released by human cells, to develop treatments intended to repair damaged tissue and address underlying disease mechanisms. KALA BIO’s lead investigational product is KPI-012, an engineered human mesenchymal stem cell secretome being developed for persistent corneal epithelial defects (PCED) associated with limbal stem cell deficiency. PCED is a rare and potentially serious condition in which the cornea does not properly heal. KPI-012 is intended to support corneal healing through multiple biological pathways. The company was formerly known as Kala Pharmaceuticals, Inc. and adopted the KALA BIO name as it shifted its focus toward regenerative medicine and rare diseases. Its operations are based in the United States, and its development programs are primarily directed toward ophthalmic conditions with significant unmet medical needs. KPI-012 remains an investigational therapy and has not been established as safe or effective for marketing purposes.AI Generated. May Contain Errors. Read More KALA BIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreKALA MarketRank™: KALA BIO scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingKALA BIO has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageKALA BIO has only been the subject of 1 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.36% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 0.39, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KALA BIO has recently increased by 10.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. News and Social Media1.4 / 5News SentimentN/A News SentimentKALA BIO has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for KALA BIO this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for KALA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have not sold or bought any company stock.Percentage Held by Insiders2.24% of the stock of KALA BIO is held by insiders.Percentage Held by Institutions24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KALA Stock News HeadlinesKALA Bio Signs LOI To Acquire Nationwide Telehealth Platform; Shares RiseSeptember 30 at 12:18 PM | rttnews.comKala Bio, Inc. And Virotek Inc. Sign Letter Of Intent With U.S. DNA Testing Platform To Resell Virotek Inc.'s Suite Of Genetic Testing ProductsSeptember 25, 2026 | marketscreener.comMThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 3 at 1:00 AM | Investors Alley (Ad)Kala Bio, Inc. und Virotek Inc. unterzeichnen Absichtserklärung mit einer US-amerikanischen DNA-Testplattform zum Weiterverkauf der genetischen Testproduktpalette von Virotek Inc.September 25, 2026 | de.marketscreener.comDKala Bio And Virotek Sign LOI To Expand Genetic Testing DistributionSeptember 24, 2026 | rttnews.comKala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing ProductsSeptember 24, 2026 | globenewswire.comKALA BIO Adds Healthcare Operator Yenvy Truong to Advisory TeamSeptember 17, 2026 | globenewswire.comKala Bio signs exclusive US distribution agreement for Virotek ophthalmology genetic testsSeptember 3, 2026 | msn.comSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $27.7950 at the start of the year. Since then, KALA stock has decreased by 98.6% and is now trading at $0.3850. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) released its quarterly earnings results on Wednesday, August, 19th. The company reported ($21.32) earnings per share for the quarter, missing analysts' consensus estimates of ($6.00) by $15.32. When did KALA BIO's stock split? Shares of KALA BIO reverse split on the morning of Monday, May 11th 2026.The 1-50 reverse split was announced on Thursday, May 7th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings8/19/2026Today10/03/2026AGM 202611/03/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (12m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KALA's financial health is in the Red zone, according to TradeSmith. KALA has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KALA CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees6Year Founded2009Profitability EPS (Trailing Twelve Months)($31.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-222.35% Return on Assets-70.23% Debt Debt-to-Equity RatioN/A Current Ratio6.88 Quick Ratio6.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.56 per share Price / Book0.03Miscellaneous Outstanding Shares19,340,000Free Float18,907,000Market Cap$7.45 million OptionableNot Optionable Beta-2.40 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KALA) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
